regulatory
confidence high
sentiment positive
materiality 0.75
SAB Biotherapeutics receives FDA Breakthrough Therapy Designation for influenza therapeutic SAB-176
SAB Biotherapeutics, Inc.
- FDA granted Breakthrough Therapy Designation to SAB-176 for post-exposure prophylaxis of Type A/B influenza in high-risk patients.
- SAB-176 previously received Fast Track designation on April 13, 2023; both designations rarely obtained together.
- Breakthrough Therapy provides intensive FDA guidance, eligibility for priority review, and expedited development.
- SAB-176 is a fully human multi-epitope binding polyclonal antibody, reducing risk of viral escape mutations.
- Phase 2b dose-ranging efficacy and safety trial planned following FDA regulatory alignment.